Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis

Gut

Volumn 63, Issue 2, 2014, Pages 236-243

  Constanza Camargo, M ^a   Kim, Woo Ho ^b   Chiaravalli, Anna Maria ^c   Kim, Kyoung Mee ^d   Corvalan, Alejandro H ^e   Matsuo, Keitaro ^f   Yu, Jun ^g   Sung, Joseph J Y ^g   Herrera Goepfert, Roberto ^h   Meneses Gonzalez, Fernando ⁱ   Kijima, Yuko ^j   Natsugoe, Shoji ^j   Liao, Linda M ^a   Lissowska, Jolanta ^k   Kim, Sung ^d   Hu, Nan ^a   Gonzalez, Carlos A ^l   Yatabe, Yashushi ^f   Koriyama, Chihaya ^j   Hewitt, Stephen M ^a   Akiba, Suminori ^j   Gulley, Margaret L ^m   Taylor, Philip R ^a   Rabkin, Charles S ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d Sungkyunkwan University   (South Korea)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

ⁱ SECRETARÍA DE SALUD   (Mexico)

^j KAGOSHIMA UNIVERSITY   (Japan)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; STOMACH CANCER; TUMOR DIFFERENTIATION;

EID: 84891738417     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-304531     Document Type: Article

References (59)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori Lyon. Vol 61. Lyon: IARC Press, 1994:177-240.
3. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. Vol 70. Lyon: IARC Press, 1997:347-73.
4. Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009;137:824-33.
5. Lee JH, Kim SH, Han SH, et al. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 2009;24:354-65.
6. Ott G, Kirchner T, Müller-Hermelink HK. Monoclonal Epstein-Barr virus genomes but lack of EBV-related protein expression in different types of gastric carcinoma. Histopathology 1994;25:323-9. (Pubitemid 24327127)
7. Akiba S, Koriyama C, Herrera-Goepfert R, et al. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci 2008;99:195-201. (Pubitemid 351228470)
8. Gao Y, Hu N, Han X, et al. Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer 2009;9:269.
9. Zhao J, Jin H, Cheung KF, et al. Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer. Cancer 2012;118:924-36.
10. Koriyama C, Akiba S, Itoh T, et al. Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan. Int J Mol Med 2002;10:635-9.
11. Kijima Y, Ishigami S, Hokita S, et al. The comparison of the prognosis between Epstein-Barr virus (EBV)-positive gastric carcinomas and EBV-negative ones. Cancer Lett 2003;200:33-40. (Pubitemid 37222356)
12. Nakao M, Matsuo K, Ito H, et al. ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infection. Cancer Epidemiol Biomarkers Prev 2011;20:1665-72.
13. Park ES, Do IG, Park CK, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res 2009;15:291-8.
14. Lee HS, Chang MS, Yang HK, et al. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin Cancer Res 2004;10:1698-705. (Pubitemid 38435561)
15. Kim RH, Chang MS, Kim HJ, et al. Medical history and lifestyle factors contributing to Epstein-Barr virus-associated gastric carcinoma and conventional gastric carcinoma in Korea. Anticancer Res 2010;30:2469-75.
16. González CA, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003;107:629-34. (Pubitemid 37296125)
17. Chiaravalli AM, Feltri M, Bertolini V, et al. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch 2006;448:344-53. (Pubitemid 43357652)
18. Chow WH, Swanson CA, Lissowska J, et al. Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland. Int J Cancer 1999;81:871-6. (Pubitemid 29249970)
19. Corvalan A, Koriyama C, Akiba S, et al. Epstein-Barr virus in gastric carcinoma is associated with location in the cardia and with a diffuse histology: a study in one area of Chile. Int J Cancer 2001;94:527-30.
20. Herrera-Goepfert R, Akiba S, Koriyama C, et al. Epstein-Barr virus-associated gastric carcinoma: evidence of age-dependence among a Mexican population. World J Gastroenterol 2005;11:6096-103. (Pubitemid 43085048)
21. Chang MS, Lee HS, Kim CW, et al. Clinicopathologic characteristics of Epstein-Barr virus-incorporated gastric cancers in Korea. Pathol Res Pract 2001;197:395-400. (Pubitemid 32544902)
22. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008;10:279-92. (Pubitemid 352022708)
23. Ryan JL, Morgan DR, Dominguez RL, et al. High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma. Lab Invest 2009;89:80-90.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
25. Smith-Warner SA, Spiegelman D, Ritz J, et al. Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol 2006;163:1053-64. (Pubitemid 43987598)
26. Nakamura S, Ueki T, Yao T, et al. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer 1994;73:2239-49. (Pubitemid 2080372)
27. Shibata D, Tokunaga M, Uemura Y, et al. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am J Pathol 1991;139:469-74.
28. Song HJ, Srivastava A, Lee J, et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 2010;139:84-92.e2.
29. Van Beek J, Zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 2004;22:664-70. (Pubitemid 41095069)
30. Shibata D, Hawes D, Stemmermann GN, et al. Epstein-Barr virus-associated gastric adenocarcinoma among Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1993;2:213-17.
31. Gulley ML, Pulitzer DR, Eagan PA, et al. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996;27:20-7. (Pubitemid 26015577)
32. Truong CD, Feng W, Li W, et al. Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U. S. A. J Exp Clin Cancer Res 2009;28:14.
33. Marur S, D'Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781-9.
34. Saiki Y, Ohtani H, Naito Y, et al. Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes. Lab Invest 1996;75:67-76. (Pubitemid 26250274)
35. Kuzushima K, Nakamura S, Nakamura T, et al. Increased frequency of antigen-specific CD8 (+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. J Clin Invest 1999;104:163-71.
36. Chiaravalli AM, Klersy C, Vanoli A, et al. Histotype-based prognostic classification of gastric cancer. World J Gastroenterol 2012;18:896-904.
37. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43:1219-23.
38. Matsunou H, Konishi F, Hori H, et al. Characteristics of Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma in Japan. Cancer 1996;77:1998-2004. (Pubitemid 26142041)
39. Murray PG, Billingham LJ, Hassan HT, et al. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 1999;94:442-7. (Pubitemid 29323858)
40. Li S, Du H, Wang Z, et al. Meta-analysis of the relationship between Epstein-Barr virus infection and clinicopathological features of patients with gastric carcinoma. Sci China Life Sci 2010;53:524-30.
41. Baghestani AR, Hajizadeh E, Fatemi SR. Parametric model to analyse the survival of gastric cancer in the presence of interval censoring. Tumori 2010;96:433-7.
42. Zhu HP, Xia X, Yu CH, et al. Application of Weibull model for survival of patients with gastric cancer. BMC Gastroenterol 2011;11:1.
43. Cammerer G, Formentini A, Karletshofer M, et al. Evaluation of important prognostic clinical and pathological factors in gastric cancer. Anticancer Res 2012;32:1839-42.
44. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
45. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006;1:375-404.
46. Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005;23:7604-13. (Pubitemid 46291824)
47. Minnicelli C, Barros MH, Klumb CE, et al. Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. PLoS One 2012;7:e46005.
48. Levine PH, Kamaraju LS, Connelly RR, et al. The American Burkitt's Lymphoma Registry: eight years' experience. Cancer 1982;49:1016-22. (Pubitemid 12184104)
49. Kijima T, Kinukawa N, Gooding WE, et al. Association of Epstein-Barr virus with tumor cell proliferation: clinical implication in nasopharyngeal carcinoma. Int J Oncol 2001;18:479-85.
50. Yip KW, Shi W, Pintilie M, et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 2006;12:5726-32. (Pubitemid 44629602)
51. Zur Hausen A, Brink AA, Craanen ME, et al. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 2000;60:2745-8. (Pubitemid 30318253)
52. Camargo MC, Murphy G, Koriyama C, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer 2011;105:38-43.
53. Matsusaka K, Kaneda A, Nagae G, et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 2011;71:7187-97.
54. Tang W, Morgan DR, Meyers MO, et al. Epstein-Barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. Infect Agent Cancer 2012;7:21.
55. Schetter AJ, You WC, Lennette ET, et al. Association of Epstein-Barr virus antibody levels with precancerous gastric lesions in a high-risk cohort. Cancer Sci 2008;99:350-4. (Pubitemid 351228491)
56. Levine PH, Stemmermann G, Lennette ET, et al. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. Int J Cancer 1995;60:642-4.
57. Shinkura R, Yamamoto N, Koriyama C, et al. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan. J Med Virol 2000;60:411-16. (Pubitemid 30127312)
58. Koshiol J, Qiao YL, Mark SD, et al. Epstein-Barr virus serology and gastric cancer incidence and survival. Br J Cancer 2007;97:1567-9. (Pubitemid 350175849)
59. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma-2nd English Edition. Gastric Cancer 1998;1:10-24.